Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa, Elvira Pelosi, Germana Castelli
Cancers (2019) Vol. 11, Iss. 9, pp. 1358-1358
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies
Lia Walcher, Ann-Kathrin Kistenmacher, Huizhen Suo, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 768
Interleukins in cancer: from biology to therapy
Daria Briukhovetska, Janina Dörr, Stefan Endres, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 8, pp. 481-499
Open Access | Times Cited: 558
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian Zheng, Ming Liu, Ya Zhang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 195
Emerging agents and regimens for AML
Hongtao Liu
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 192
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
May Daher, Katayoun Rezvani
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 45-58
Open Access | Times Cited: 173
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter, Katie Hege, Jay Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 166
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
Hui Lü, Xiaoyan Zhao, Ziying Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 89
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
Hind Rafei, May Daher, Katayoun Rezvani
British Journal of Haematology (2020) Vol. 193, Iss. 2, pp. 216-230
Open Access | Times Cited: 87
Biological Characteristics of Umbilical Cord Mesenchymal Stem Cells and Its Therapeutic Potential for Hematological Disorders
Yufeng Shang, Haotong Guan, Fuling Zhou
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 62
The EBMT/EHA CAR-T Cell Handbook
Nicolaus Kröger, John G. Gribben, Christian Chabannon, et al.
Springer eBooks (2022)
Closed Access | Times Cited: 58
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
Mayumi Sugita, Román Galetto, Hongliang Zong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 45
Immunotargeting of Cancer Stem Cells
Ayşe Sedef Köseer, Simona Di Gaetano, Claudia Arndt, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1608-1608
Open Access | Times Cited: 30
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
Elvira Pelosi, Germana Castelli, Ugo Testa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2718-2718
Open Access | Times Cited: 24
TP53 in MDS and AML: Biological and clinical advances
Yeqian Zhao, Weihao Chen, Jing Yu, et al.
Cancer Letters (2024) Vol. 588, pp. 216767-216767
Closed Access | Times Cited: 14
Inhibitory CARs fail to protect from immediate T cell cytotoxicity
Maximilian A. Funk, Gerwin Heller, Petra Waidhofer‐Söllner, et al.
Molecular Therapy (2024) Vol. 32, Iss. 4, pp. 982-999
Open Access | Times Cited: 13
Challenges and innovations in CAR-T cell therapy: a comprehensive analysis
Jingming Luo, Xianwen Zhang
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 13
Recent advances of CAR-T cells in acute myeloid leukemia
Huan Deng, Qi Wang, Xiaodong Tong, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access | Times Cited: 1
Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development
Michele Stanchina, Deborah Soong, Binbin Zheng-Lin, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3225-3225
Open Access | Times Cited: 62
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Matteo Libero Baroni, Diego Sánchez‐Martínez, Francisco Gutiérrez Agüera, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000845-e000845
Open Access | Times Cited: 53
Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges
Giovanni Riva, Vincenzo Nasillo, Anna Maria Ottomano, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4582-4582
Open Access | Times Cited: 44
IL-3 in the development and function of basophils
Gilda Varricchi, Remo Poto, Gianni Marone, et al.
Seminars in Immunology (2021) Vol. 54, pp. 101510-101510
Closed Access | Times Cited: 42
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 567-578
Open Access | Times Cited: 31
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia‐Manero, et al.
Blood Advances (2022) Vol. 6, Iss. 10, pp. 3027-3035
Open Access | Times Cited: 30
CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
Xin Jin, Danni Xie, Rui Sun, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
Andrew A. Lane, Jacqueline S. Garcia, Evangeline G. Raulston, et al.
Blood Advances (2023) Vol. 8, Iss. 3, pp. 591-602
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top